165 related articles for article (PubMed ID: 35511608)
1. Human Immunodeficiency Virus Is Associated With Elevated FibroScan-Aspartate Aminotransferase (FAST) Score.
Price JC; Ma Y; Kuniholm MH; Adimora AA; Fischl M; French AL; Golub ET; Konkle-Parker D; Minkoff H; Ofotokun I; Plankey M; Sharma A; Tien PC
Clin Infect Dis; 2022 Dec; 75(12):2119-2127. PubMed ID: 35511608
[TBL] [Abstract][Full Text] [Related]
2. Fibroscan-Aspartate Aminotransferase Score Predicts Liver-Related Outcomes, but Not Extrahepatic Events, in a Multicenter Cohort of People With Human Immunodeficiency Virus.
Sebastiani G; Milic J; Kablawi D; Gioè C; Al Hinai AS; Lebouché B; Tsochatzis E; Finkel J; Ballesteros LR; Ramanakumar AV; Bhagani S; Benmassaoud A; Mazzola G; Cascio A; Guaraldi G
Clin Infect Dis; 2023 Aug; 77(3):396-404. PubMed ID: 37013396
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV.
Michel M; Labenz C; Wahl A; Anders M; Armandi A; Huber Y; Galle PR; Sprinzl M; Schattenberg JM
AIDS; 2022 Oct; 36(12):1665-1674. PubMed ID: 35849074
[TBL] [Abstract][Full Text] [Related]
4. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
[TBL] [Abstract][Full Text] [Related]
6. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
[TBL] [Abstract][Full Text] [Related]
7. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse.
Sterling RK; Smith PG; Brunt EM
J Clin Gastroenterol; 2013 Feb; 47(2):182-7. PubMed ID: 23059409
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D;
J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529
[TBL] [Abstract][Full Text] [Related]
9. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
[TBL] [Abstract][Full Text] [Related]
10. FibroScan-aspartate aminotransferase score in an Asian cohort of non-alcoholic fatty liver disease and its utility in predicting histological resolution with bariatric surgery.
Anand A; Elhence A; Vaishnav M; Singh AA; Rajput MS; Banyal V; Jindal V; Pathak P; Kumar P; Nayak B; Yadav R; Das P; Garg H; Agarwal L; Aggarwal S; Kumar R; Shalimar
J Gastroenterol Hepatol; 2021 May; 36(5):1309-1316. PubMed ID: 33232525
[TBL] [Abstract][Full Text] [Related]
11. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.
Loong TC; Wei JL; Leung JC; Wong GL; Shu SS; Chim AM; Chan AW; Choi PC; Tse YK; Chan HL; Wong VW
J Gastroenterol Hepatol; 2017 Jul; 32(7):1363-1369. PubMed ID: 27936280
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic Steatohepatitis and Hepatic Fibrosis in HIV-1-Monoinfected Adults With Elevated Aminotransferase Levels on Antiretroviral Therapy.
Morse CG; McLaughlin M; Matthews L; Proschan M; Thomas F; Gharib AM; Abu-Asab M; Orenstein A; Engle RE; Hu X; Lempicki R; Hadigan C; Kleiner DE; Heller T; Kovacs JA
Clin Infect Dis; 2015 May; 60(10):1569-78. PubMed ID: 25681381
[TBL] [Abstract][Full Text] [Related]
13. The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan-aspartate aminotransferase to predict severity of liver disease in children.
Chaidez A; Pan Z; Sundaram SS; Boster J; Lovell M; Sokol RJ; Mack CL
Hepatol Commun; 2022 Nov; 6(11):3015-3023. PubMed ID: 36069338
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of High-risk Nonalcoholic Steatohepatitis (NASH) in the United States: Results From NHANES 2017-2018.
Vilar-Gomez E; Vuppalanchi R; Mladenovic A; Samala N; Gawrieh S; Newsome PN; Chalasani N
Clin Gastroenterol Hepatol; 2023 Jan; 21(1):115-124.e7. PubMed ID: 34958922
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.
Tamaki N; Imajo K; Sharpton S; Jung J; Kawamura N; Yoneda M; Valasek MA; Behling C; Sirlin CB; Nakajima A; Loomba R
Hepatology; 2022 Mar; 75(3):661-672. PubMed ID: 34496054
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
17. Impact of steatotic liver disease and non-alcoholic steatohepatitis on cognitive impairment in people living with HIV: A cross-sectional study.
Han WM; Hiransuthikul A; Holroyd KB; Apornpong T; Lwin HM; Gatechompol S; Ubolyam S; Kerr S; Avihingsanon A;
HIV Med; 2023 Dec; 24(12):1233-1243. PubMed ID: 37975283
[TBL] [Abstract][Full Text] [Related]
18. Poor Concordance Between Liver Stiffness and Noninvasive Fibrosis Scores in HIV Infection Without Viral Hepatitis.
Kirkegaard-Klitbo DM; Bendtsen F; Lundgren J; Nielsen SD; Benfield T;
Clin Gastroenterol Hepatol; 2020 Dec; 18(13):3049-3050. PubMed ID: 31648031
[TBL] [Abstract][Full Text] [Related]
19. Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults.
Sterling RK; King WC; Wahed AS; Kleiner DE; Khalili M; Sulkowski M; Chung RT; Jain MK; Lisker-Melman M; Wong DK; Ghany MG;
Hepatology; 2020 Feb; 71(2):411-421. PubMed ID: 31220357
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy.
Perazzo H; Cardoso SW; Yanavich C; Nunes EP; Morata M; Gorni N; da Silva PS; Cardoso C; Almeida C; Luz P; Veloso VG; Grinsztejn B
J Int AIDS Soc; 2018 Nov; 21(11):e25201. PubMed ID: 30394678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
